To Get Help Now
Click Here
 
Today's Date:

Actos Bladder Cancer Lawsuits Seek Consolidation

AddThis Social Bookmark Button

Plaintiffs Glen and Nina Weant have filed a motion requesting that all federally filed lawsuits against Takeda Pharmaceuticals alleging the drug company failed to adequately research Actos and warn about the increased risk of bladder cancer for those who use Actos for an extended period, be consolidated before Judge G. Patrick Murphy in the U.S. District Court for the Southern District of Illinois for pretrial proceedings as part of a multidistrict litigation (MDL).

The motion to consolidate current cases, of which there are about 12, comes of the expectation of hundreds of complaints to be filed by patients who have developed bladder cancer because of Actos use.

Actos is a type 2 diabetes drug approved by the FDA in 1999. The potential risk of bladder cancer development associated with long-term Actos use came under FDA investigations in 2010, after data from a 10 year study showed that after 24 months, users of Actos experienced a statistically significant increased risk of developing bladder cancer.

France recalled Actos from the market in June 2010, and the European Medicines Agency called for new warnings and a review of every patient taking the drug.

The Panel on Multidistrict Litigation will probably not schedule a hearing on the request until a hearing session scheduled for December 1, 2011.

 

breakinglawsuitnews.com disclaimer: This article: Actos Bladder Cancer Lawsuits Seek Consolidation was posted on Wednesday, September 14th, 2011 at 7:16 pm at breakinglawsuitnews.com and is filed under Defective Drug Lawsuits.

« »

Leave a Reply

You must be logged in to post a comment.